MSCoViD Scaling of GMP production of human umbilical cord mesenchymal stromal cells for the treatment of CoViD19 patients with moderate to severe acute respiratory distress syndrome
- Funded by ANR
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
ANRPrincipal Investigator
Danièle BensoussanResearch Location
FranceLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The MSCoViD project aims to scale up the production under GMP condition of human umbilical cord mesenchymal stromal cells in order to conduct efficacy clinical trials for the treatment of COVID-19 patients with moderate to severe acute respiratory distress syndrome. It will rely on the complementary and multidisciplinary expertise (cell therapy, MSC biology, bioprocess engineering) of each of the partners.